The Russell 2000 has crushed the S&P over the past month. Here's why traders continue to favor small caps.» Read More
Even beyond talk of a "June swoon," an unusual number of major events makes this month a critical time for markets.
Top tech investor Paul Meeks updates his "Squawk Box Platinum Portfolio" in these unexpected sectors.
CNBC's Fast Money team takes a look at five technology stocks that are set to fly higher.
Jim Cramer kicks off his healthcare hot list with one scorching name that does well in a slow growth economy.
The "Fast Money" traders give their final trades of the day.
Why it's time to strengthen your core portfolio.
Jim Cramer speaks to the CEO of Target on how he managed to turn around the business, and its new collaboration with Lilly Pulitzer.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
While new economic data painted a mixed picture on the economy, two economists believe the economy should continue to recover.
Companies finally may be getting the message that it's better to invest in the future.
Check out the companies making headlines after the bell Monday: Netapp, PVH, Old Dominion Freight & more.
Singularity-CNBC conference kicks off
One influential economist is saying investors need not worry about current valuations, and he has a 45-year chart to prove his point.
Top technician Carter Worth says Apple and biotech look "married." He explains why they are the must-own names in the market right now.
Airline deregulation fostered new players. Now, financial regulation is enabling nimble start-ups in financial services, Stephen Dash says.
The argument for including mainland China in MSCI's Emerging Markets Index is a fairly simple one: It is underweighted in global indices.
"Our 40 percent 'grey sky' scenario for European equity returns to end-2016 is based on three key factors," according to Citi.
Technical analyst Craig Johnson shows why the U.S. dollar could be set to shoot higher.
The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.
Equities will be the riskiest asset class this year and through the next decade, but will also offer the highest returns, a poll predicted on Monday.